A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder
about
Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressantsNeuroplasticity and the next wave of antidepressant strategiesPreclinical evidence of rapid-onset antidepressant-like effect in Radix Polygalae extractKetamine and other glutamate receptor modulators for depression in adultsRapid antidepressant effects: moving right alongPreclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonistPotential of Glutamate-Based Drug Discovery for Next Generation AntidepressantsGlial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?Antidepressant actions of ketamine: from molecular mechanisms to clinical practiceTargeting the glutamatergic system to treat major depressive disorder: rationale and progress to dateGLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonistsA brief history of the development of antidepressant drugs: from monoamines to glutamateThe role of GluN2A and GluN2B subunits on the effects of NMDA receptor antagonists in modeling schizophrenia and treating refractory depressionGlutamate and its receptors in the pathophysiology and treatment of major depressive disorderExperimental medication treatment approaches for depression.Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.Ketamine as a potential treatment for suicidal ideation: a systematic review of the literatureMultiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approachA randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.New targets for rapid antidepressant action.Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.Investigational drugs in recent clinical trials for treatment-resistant depression.Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.Beyond serotonin: newer antidepressants in the future.Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.Rodent models of treatment-resistant depression.Influence of Genetic Variants of the N-Methyl-D-Aspartate Receptor on Emotion and Social Behavior in AdolescentsNovel Glutamatergic Treatments for Severe Mood Disorders.A Novel Binding Mode Reveals Two Distinct Classes of NMDA Receptor GluN2B-selective AntagonistsRapid-acting glutamatergic antidepressants: the path to ketamine and beyond.Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological TreatmentsCurrent status of ketamine and related compounds for depressionDysfunctional astrocytic and synaptic regulation of hypothalamic glutamatergic transmission in a mouse model of early-life adversity: relevance to neurosteroids and programming of the stress response.Therapeutic Modulation of Glutamate Receptors in Major Depressive DisorderTowards the Molecular Foundations of Glutamatergic-targeted Antidepressants.Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin.Novel glutamatergic drugs for the treatment of mood disorders.NMDA antagonists under investigation for the treatment of major depressive disorder.
P2860
Q21129276-066BD038-DD3C-463D-9454-33FB3D854192Q21129480-E49ECD32-312D-4793-A7EF-A5CDB02F86ACQ21132322-1C4DDC29-0D99-44B8-AABE-254A40488378Q24186746-4588A6B2-F3D2-491A-AA1E-AD55D5E7AAC2Q24614410-521A18FE-E833-4939-8639-56549E3E3F12Q26750021-0717F505-2FA0-49B0-893A-9CC9A8FD5C63Q26782274-C300EFF6-01D9-48A8-AE4E-81A1239298E2Q26829556-2FFC7EFA-59F2-4C2C-B1D8-3DDA873AE216Q26995879-ED870A08-47F0-4B81-B132-C0893413E261Q27004490-861F4753-590E-45CF-8B14-92E7807DAA9DQ27025974-EEA1C78B-68A7-4C19-9AE7-609065BF40DFQ27028050-D88F07BF-7178-488B-9F80-56D3D46472E5Q30595767-986D9694-0D1B-4419-B0F2-30A744D271F4Q30711088-BE9902D1-8F3D-44FD-97DF-9F7CE073D627Q33635577-40C4C4D1-693E-4BD7-90AE-753D8DA70A22Q33874459-612DFBED-991B-4E0B-95FE-A2A086586FD9Q34043478-F5D214D7-E4D7-41E3-B665-E8CD96B635E4Q34268501-BE07636D-068D-4B61-B3C0-5D95191EE086Q34315128-B1BFF10E-33C4-4B46-96A5-817F5D848A40Q34330678-3320208F-0090-4D2E-B06C-DD2F33053D66Q34475595-7C6B72DF-26C9-4B38-9768-3470B6B12C87Q34507177-A120D6DC-C1DE-4814-8A9D-61B1BCEFA331Q34512818-D4B4B82D-DA68-4D66-AFC0-C8F519D1FB8DQ34549390-B634A145-ED60-4B21-81D8-92F9AD8E9D3FQ34551188-269DAFCB-5B37-4DF0-938B-443EE32BB856Q34557706-05A5451C-F844-45FB-9BC3-BCC1F59B6E03Q34653386-2DEFA2C0-D1E3-49D1-8E25-3079532129F4Q35580361-FA677285-4E83-412E-9710-1C4B78BE2C48Q36447192-F973930E-2D1D-489C-BC76-B414AC732E83Q36498659-A2EA21E2-EA4A-42F3-8D89-9FBC4359BD0EQ36879280-518A2D2E-920A-4FA0-9415-A98B8C10FCCAQ36899381-B5EA848B-6BB9-4F1F-8B51-0C6A810EFDB9Q37197216-B281D0F7-6670-438F-9A9D-2042D752DCB5Q37202885-A7F6054E-6AC8-4832-BB9B-AD57BC4943E9Q37381812-0DE7DCB6-1CC3-417B-AC94-62411C7961A0Q37668014-F427ACF4-88CC-4663-BC45-E2B45FD5308CQ37668029-9DADE795-84C8-4C03-9A5C-82652261B937Q38061522-14B031AA-6578-447C-9FB1-59958D89977EQ38131480-180BA902-CB94-4604-83A4-C099148B94E5Q38211107-2CE59B17-8AFF-4E26-9A11-5246BCE513C3
P2860
A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A Randomized, placebo-controll ...... tant major depressive disorder
@ast
A Randomized, placebo-controll ...... tant major depressive disorder
@en
A Randomized, placebo-controll ...... tant major depressive disorder
@nl
type
label
A Randomized, placebo-controll ...... tant major depressive disorder
@ast
A Randomized, placebo-controll ...... tant major depressive disorder
@en
A Randomized, placebo-controll ...... tant major depressive disorder
@nl
prefLabel
A Randomized, placebo-controll ...... tant major depressive disorder
@ast
A Randomized, placebo-controll ...... tant major depressive disorder
@en
A Randomized, placebo-controll ...... tant major depressive disorder
@nl
P2093
P2860
P1476
A Randomized, placebo-controll ...... tant major depressive disorder
@en
P2093
Carlos A Zarate
David A Luckenbaugh
Libby Jolkovsky
Lobna Ibrahim
Nancy Brutsche
W Joseph Herring
William Z Potter
P2860
P304
P356
10.1097/JCP.0B013E31825D70D6
P407
P577
2012-08-01T00:00:00Z